Background: Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ). Because PPAR-γ initiates a variety of antiinflammatory responses, the effect on myocardial ischemia is to be elucidated.
Methods and Results: The left anterior descending arteries were ligated to induce myocardial infarction in rats. The animals were assigned to 4 groups: (1) control (saline, n = 6), (2) telmisartan (10 mg·kg−1·d−1, n = 6), (3) telmisartan + GW9662 (PPAR-γ-antagonist) (10 mg·kg−1·d−1 of telmisartan and 1 mg·kg−1·d−1 of GW9662, n = 6), and (4) amlodipine (10 mg·kg−1·d−1, n = 8) groups. Telmisartan reduced mean blood pressure compared with that in the control group. There was no statistical difference among the telmisartan, telmisartan + GW9662 and amlodipine groups. The end-diastolic left ventricular diameter was smaller in telmisartan group compared with that in the control group; GW9662 negated the effect of telmisartan. The thickness of the ventricular septum was kept in the telmisartan group compared with that in the control group; GW9662 negated the effect. Histopathologic analyses showed that telmisartan suppressed myocardial fibrosis compared with that of the control, whereas GW9662 negated the telmisartan effect.
Conclusions: Telmisartan suppresses pathological remodeling by PPAR-γ agonistic activities independent of its antihypertensive effects.
*Department of Cardiovascular Medicine, Tokyo Medical and Dental University
†Department of Advanced Clinical Science and Therapeutics, University of Tokyo, Bunkyo-ku, Tokyo
‡NB Health Laboratory, Kamiaoki, Saitama
§Department of Cardiovascular Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Reprints: Jun-ichi Suzuki, MD, PhD, Department of Advanced Clinical Science and Therapeutics, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan (e-mail: email@example.com).
The authors declare no conflicts of interest.
Received February 8, 2012
Accepted April 5, 2012